An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer

Trial Profile

An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2015

At a glance

  • Drugs Ganetespib (Primary)
  • Indications Advanced breast cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ENCHANT; ENCHANT-1
  • Sponsors Synta Pharmaceuticals
  • Most Recent Events

    • 08 Jul 2014 UKCRN reports trial status as active, no longer recruiting.
    • 08 May 2014 Status changed from recruiting to discontinued as reported in a Synta Pharmaceuticals media release.
    • 07 Apr 2014 Results from a gene expression and proteomic analysis of this trial will be presented at the 2014 Annual Meeting of the American Association of Cancer Research according to a Synta Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top